{"id":"theophylline-anhydrous-oral-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea and vomiting"},{"rate":"5-15%","effect":"Headache"},{"rate":"5-10%","effect":"Tachycardia"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"1-5%","effect":"Arrhythmias"},{"rate":"<1%","effect":"Seizures (at toxic levels)"}]},"_chembl":{"chemblId":"CHEMBL190","moleculeType":"Protein","molecularWeight":"180.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Theophylline works primarily by inhibiting phosphodiesterase enzymes, which prevents the breakdown of cyclic nucleotides (cAMP and cGMP) in smooth muscle and immune cells. This leads to relaxation of bronchial smooth muscle, resulting in bronchodilation. Additionally, theophylline has immunomodulatory properties including reduced inflammatory mediator release from mast cells and eosinophils, and enhanced diaphragmatic contractility.","oneSentence":"Theophylline is a nonselective phosphodiesterase inhibitor that increases intracellular cAMP and cGMP, producing bronchodilation and anti-inflammatory effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:12.605Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (chronic maintenance therapy)"},{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Apnea of prematurity"}]},"trialDetails":[{"nctId":"NCT04257851","phase":"PHASE4","title":"Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache","status":"COMPLETED","sponsor":"Damanhour Teaching Hospital","startDate":"2020-02-15","conditions":"Post-Dural Puncture Headache","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Quibron-T/SR tablets"],"phase":"marketed","status":"active","brandName":"Theophylline Anhydrous Oral Tablet","genericName":"Theophylline Anhydrous Oral Tablet","companyName":"Damanhour Teaching Hospital","companyId":"damanhour-teaching-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Theophylline is a nonselective phosphodiesterase inhibitor that increases intracellular cAMP and cGMP, producing bronchodilation and anti-inflammatory effects. Used for Asthma (chronic maintenance therapy), Chronic obstructive pulmonary disease (COPD), Apnea of prematurity.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}